Evidence map›Paper›PMID 41566873›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Discovery of novel and highly potent XIAP-targeted peptide inhibitors using virtual screening.

Xiaoliang Wang, Mengting Lou, Yuting Wang, Miao-Miao Niu, Dongli Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaoliang WangDepartment of Proctology, Taizhou Hospital of Traditional Chinese Medicine, Taizhou, Jiangsu, China.
Mengting LouDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Yuting WangDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Miao-Miao NiuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Dongli ZhangDepartment of Gastroenterology, Taizhou School of Clinical Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer, a globally prevalent fatal malignancy, remains a major therapeutic challenge. X-linked inhibitor of apoptosis protein (XIAP) is overexpressed in various cancers, driving uncontrolled proliferation, while its specific inhibition suppresses tumour growth. Through virtual screening, we identified five novel candidate peptides (Peptides 1-5) with picomolar-level inhibitory activity. Peptide-5 showed the highest binding affinity (

Indexed as

Antineoplastic AgentsDrug DiscoveryPeptidesX-Linked Inhibitor of Apoptosis ProteinApoptosisCell ProliferationDose-Response Relationship, DrugDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsPeptidesXIAP protein, humanX-Linked Inhibitor of Apoptosis Proteinlung cancermolecular dockingvirtual screeningX-linked inhibitor of apoptosis protein (XIAP)

Identifiers

PMID41566873
PMCPMC12829411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.